Athira Pharma, Inc. financial data

Symbol
ATHA on Nasdaq
Location
Bothell, WA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 631% % 46%
Debt-to-equity 19% % -36%
Return On Equity -107% % 7.4%
Return On Assets -90% % -1.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3,943,887 shares -90%
Common Stock, Shares, Outstanding 3,943,887 shares -90%
Entity Public Float $86,000,000 USD -11%
Common Stock, Value, Issued $4,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 3,943,887 shares 2.4%
Weighted Average Number of Shares Outstanding, Diluted 3,943,887 shares 2.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $20,158,000 USD -76%
General and Administrative Expense $19,109,000 USD -29%
Costs and Expenses $39,267,000 USD -66%
Operating Income (Loss) $39,267,000 USD 66%
Net Income (Loss) Attributable to Parent $37,723,000 USD 65%
Earnings Per Share, Basic 4 USD/shares 77%
Earnings Per Share, Diluted 4 USD/shares 77%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $20,874,000 USD -70%
Assets, Current $27,025,000 USD -67%
Property, Plant and Equipment, Net $1,715,000 USD -36%
Operating Lease, Right-of-Use Asset $607,000 USD -30%
Other Assets, Noncurrent $55,000 USD 0%
Assets $30,033,000 USD -65%
Accounts Payable, Current $266,000 USD -31%
Employee-related Liabilities, Current $509,000 USD -89%
Accrued Liabilities, Current $2,069,000 USD -88%
Liabilities, Current $2,787,000 USD -90%
Operating Lease, Liability, Noncurrent $460,000 USD -50%
Liabilities $3,247,000 USD -89%
Accumulated Other Comprehensive Income (Loss), Net of Tax $2,000 USD -167%
Retained Earnings (Accumulated Deficit) $428,866,000 USD -9.6%
Stockholders' Equity Attributable to Parent $26,786,000 USD -53%
Liabilities and Equity $30,033,000 USD -65%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $14,665,000 USD 43%
Net Cash Provided by (Used in) Investing Activities $7,351,000 USD -156%
Common Stock, Shares Authorized 90,000,000 shares -90%
Common Stock, Shares, Issued 3,943,887 shares -90%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $22,016,000 USD -72%
Deferred Tax Assets, Valuation Allowance $91,949,000 USD 29%
Deferred Tax Assets, Gross $92,235,000 USD 29%
Operating Lease, Liability $912,000 USD -31%
Depreciation $971,000 USD 9.5%
Payments to Acquire Property, Plant, and Equipment $5,000 USD -98%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $37,728,000 USD 65%
Lessee, Operating Lease, Liability, to be Paid $981,000 USD -33%
Property, Plant and Equipment, Gross $5,739,000 USD 0%
Operating Lease, Liability, Current $452,000 USD 12%
Lessee, Operating Lease, Liability, to be Paid, Year Two $346,000 USD -32%
Lessee, Operating Lease, Liability, to be Paid, Year One $509,000 USD 3%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $69,000 USD -56%
Deferred Tax Assets, Operating Loss Carryforwards $43,414,000 USD 39%
Unrecognized Tax Benefits $4,121,000 USD 33%
Share-based Payment Arrangement, Expense $6,873,000 USD -38%